1) Problem framing and goals
- Ambition vs reality: “Curing cancer with AI tomorrow” is not feasible. A high-impact, near-term objective is to improve patient selection and hypothesis generation for immunotherapy (PD-1/PD-L1), where heterogeneous benefit and toxicity remain major unmet needs. We will develop and externally validate a multimodal, pretreatment predictor of immune checkpoint inhibitor (ICI) benefit with transparent reporting and clinical utility analysis. We will adhere to TRIPOD+AI reporting, assess risk of bias with PROBAST+AI, and quantify clinical net benefit via Decision Curve Analysis (DCA). [2][3][1]
- Primary goal: Build, calibrate, and externally validate a pretreatment model that predicts objective response and survival (PFS/OS) to anti–PD-1/PD-L1 using transcriptomics, tumor mutational burden (TMB), PD-L1, histology whole-slide images (WSI) where available, and clinical covariates. Evaluate clinical utility with DCA and prepare for early-stage prospective silent evaluation per DECIDE-AI. [1][6]
- Scope and cohorts: Urothelial carcinoma (IMvigor210) and melanoma (Hugo 2016; Riaz 2017/2018; Gide 2019) as development and external-validation sets, reflecting diverse tumor-immune contexts. [9][10][7][8]
- Secondary goals:
  - Quantify incremental value of each modality (RNA, WSI, TMB, PD-L1) beyond standard biomarkers.
  - Assess transportability across tumor types and sites.
  - Provide mechanistic interpretability linking model signals to known T cell states and immune pathways. [7]
  - Prepare protocol and guardrails for prospective evaluation (SPIRIT-AI, DECIDE-AI, CONSORT-AI). [5][6][4]

2) Experiments
All experiments use nested cross-validation within cohort, external validation across cohorts, calibration (reliability curves, Brier score), net benefit via DCA, and transparent reporting (TRIPOD+AI). [2][3][1]

Experiment 1: Multimodal fusion vs. unimodal
- Hypothesis: Multimodal fusion (RNA-seq features + TMB + PD-L1 ± WSI + clinical) improves discrimination and calibration over any single biomarker. 
- Setup: 
  - Data: IMvigor210 (bladder, anti–PD-L1) for development; external validation on melanoma ICI cohorts (Hugo 2016; Riaz 2017/2018; Gide 2019). [9][10][7][8]
  - Models: Logistic/XGBoost baselines; multimodal late fusion; survival extensions with Cox/XGBoost-Survival.
  - Preprocessing: RNA TPM/log-CPM with batch mitigation (e.g., ComBat); standardized PD-L1; harmonized TMB; basic clinical variables.
- Baselines: TMB alone, PD-L1 alone, published RNA signatures (e.g., IFN-γ), and clinical-only models; report decision curves for each. [1]
- Evaluation metrics: AUC-ROC/PR for response; C-index for PFS/OS; Brier; calibration slope; net benefit (DCA). [1]
- Expected outcomes: Fusion improves AUC by 0.05–0.10 over the best unimodal baseline and yields higher net benefit across clinically plausible thresholds. If not observed, we will quantify conditions where the added modality harms performance (negative transfer). (Conjecture, to be tested.)

Experiment 2: Histology WSI signal and incremental value
- Hypothesis: WSI-derived features capture tumor-immune microenvironment signals that improve prediction beyond RNA/TMB/PD-L1, consistent with literature showing pathology-based biomarker prediction (e.g., MSI) from H&E with Transformers. [P8]
- Setup:
  - WSI feature extraction with weakly supervised MIL/Transformer (e.g., CLAM/TIA/MONAI), stain normalization, tile-level QC.
  - Integrate WSI features with RNA/TMB/PD-L1 via late fusion.
  - If ICI datasets lack WSIs, conduct a proxy feasibility study: predict established biomarkers (MSI, TMB-high) in matched cohorts to demonstrate WSI signal and then evaluate transferability. [P8]
- Baselines: WSI-only model; RNA-only; TMB-only; combined without WSI.
- Metrics: Same as E1; plus net reclassification improvement and decision curves. [1]
- Expected outcomes: Modest but significant improvement in discrimination and net benefit when WSI is added to RNA/TMB/PD-L1; if unavailable, establish feasibility via proxy targets first. [P8]

Experiment 3: Cross-cohort and cross-cancer generalization
- Hypothesis: Immune-inflamed transcriptomic programs and T-cell states associated with ICI response generalize across tumor types, but effect sizes attenuate with domain shift. [7][8]
- Setup: Train on bladder (IMvigor210), test on melanoma cohorts and vice versa; assess domain adaptation (e.g., CORAL) and batch correction strategies.
- Baselines: In-domain training and evaluation.
- Metrics: Drop in AUC/C-index vs in-domain; calibration drift; feature stability; PROBAST+AI risk of bias and applicability assessment. [3]
- Expected outcomes: AUC degradation on out-of-domain data revealing robust vs. context-specific features; guidance for domain adaptation.

Experiment 4: Clinical utility and treatment policy simulation
- Hypothesis: At realistic decision thresholds (e.g., selecting top x% for ICI monotherapy), the model provides positive net benefit and acceptable number-needed-to-treat compared with treat-all or biomarker-only strategies. 
- Setup: Use external validation sets; simulate triage policies (e.g., refer low-score patients to alternative regimens/clinical trials).
- Metrics: Decision curves (net benefit vs threshold), NNT, avoidable non-benefit, and number of missed responders. [1]
- Expected outcomes: A threshold band with superior net benefit vs. guideline biomarker comparators (PD-L1/TMB); if not, define required model performance to justify deployment. [1]

Experiment 5: Mechanistic interpretability and biological plausibility
- Hypothesis: Learned features align with T-cell inflamed states and interferon/cytotoxic signatures associated with response. [7]
- Setup: SHAP and pathway enrichment; compare top RNA features to T-cell state markers (Sade-Feldman 2018) and immune cell composition; interrogate WSI tiles for immune hotspots.
- Baselines: Randomized labels and permuted features to test for spurious interpretability.
- Metrics: Enrichment FDRs; stability across cohorts; expert pathologist review for WSI.
- Expected outcomes: Enrichment of IFN-γ signaling, CXCL9/10, GZMB; WSI tiles highlighting immune infiltration patterns aligned with responders. [7]

Experiment 6: Survival modeling for delayed effects
- Hypothesis: Mixture and non-proportional hazard survival models better capture immunotherapy-specific survival dynamics (e.g., cure fraction, delayed separation of curves) than standard Cox. [P2]
- Setup: Compare Cox, flexible parametric, and mixture-cure models on PFS/OS; assess calibration plots by time.
- Metrics: Time-dependent C-index, IBS, calibration, and AIC/BIC.
- Expected outcomes: Improved fit and calibration with mixture/flexible models; better clinical interpretability for long-term benefit. [P2]

Experiment 7: Prospective readiness and early-stage evaluation
- Hypothesis: A shadow (silent) deployment is feasible with stable outputs, timely inference, and clinician acceptance, per DECIDE-AI; trial protocol elements per SPIRIT-AI and reporting per CONSORT-AI. [6][5][4]
- Setup: 4–6 week silent run in clinic with locked model; capture time-to-result, missingness, override reasons; pre-specify endpoints and analysis.
- Metrics: Uptime, inference latency, missing data rate, usability feedback; pre-post process metrics.
- Expected outcomes: Operational feasibility and refined protocol/consent artifacts for a future interventional study. [6][5][4]

3) Timeline for the next 6 months with milestones
- Month 0–1:
  - Finalize analysis plan; pre-register TRIPOD+AI-compliant protocol; ethics/IRB for data use and silent deployment. [2][5]
  - Acquire and harmonize datasets: IMvigor210, Hugo 2016, Riaz 2017/2018, Gide 2019; define endpoints and censoring rules. Note: Public links for IMvigor210 R package were not retrieved directly; if unavailable, use consolidated sources (e.g., easierData) or original GEO/SRA/EGAS access. [9] Limitation: precise official IMvigor210 R package link not surfaced; we will retrieve via Bioconductor or corresponding author as needed.
- Month 2:
  - Preprocessing pipelines for RNA/TMB/PD-L1/clinical; implement unimodal baselines; initial WSI extraction if slides available.
  - Establish nested CV and external validation harness; baseline DCA. [1]
- Month 3:
  - Train multimodal fusion models; feature selection; calibration; model cards; interpretability analyses.
  - Survival modeling (Cox vs flexible vs mixture). [P2]
- Month 4:
  - Cross-cohort generalization experiments; finalize external validation; decision curve and policy simulations.
  - Draft Results; complete PROBAST+AI risk-of-bias assessment. [3]
- Month 5:
  - Mechanistic validation (pathways, T-cell states); pathology expert review of WSI tiles; robustness/batch analyses.
  - Prepare DECIDE-AI-compliant shadow deployment protocol and artifacts. [6]
- Month 6:
  - Shadow deployment run; collect process metrics and feedback; finalize manuscript (TRIPOD+AI), code, model card, and preprint submission. [2]

4) Resources (compute, tools, datasets)
- Compute and storage:
  - 2× GPUs (e.g., A100 40GB or 3090/4090) for WSI; CPU cluster for RNA/TMB processing; 5–10 TB storage for WSIs; encrypted PHI-safe environment if using clinical data.
- Software:
  - Python: scikit-learn, XGBoost, PyTorch/Lightning, MONAI, TIAToolbox/CLAM for WSI MIL; lifelines/pycox for survival; shap; statsmodels; dcav for decision curves or custom per Vickers. [1]
  - R: Bioconductor for data access (e.g., IMvigor210/easierData proxies), survival, rms, rmda for DCA; TRIPOD+AI/PROBAST+AI checklists. [2][3]
- Datasets:
  - IMvigor210 (urothelial carcinoma, anti–PD-L1): expression, PD-L1, mutations, clinical; R package or alternative sources such as easierData; verify licensing. Limitation: direct official package link not surfaced here; we will obtain via Bioconductor or authors. [9]
  - Melanoma anti–PD-1: Hugo 2016 Cell, Riaz 2017/2018 Cell; Gide 2019 Cancer Cell (PD-1 vs PD-1+CTLA-4). [10][7][8]
  - Optional: TCGA for proxy WSI biomarker modeling (MSI/TMB-high) if ICI WSIs unavailable. [P8]

5) Risks and mitigations
- Small sample sizes and class imbalance in ICI cohorts
  - Mitigation: Nested CV, external validation, uncertainty quantification, conservative feature selection, report optimism-adjusted performance (TRIPOD+AI). [2]
- Dataset shift and batch effects across cohorts
  - Mitigation: Harmonized preprocessing, ComBat/batch-aware modeling, domain adaptation, transportability tests; PROBAST+AI applicability assessment. [3]
- Label noise and outcome heterogeneity (RECIST dynamics, pseudo-progression)
  - Mitigation: Sensitivity analyses (alternate endpoints, landmarking), survival modeling that captures delayed effects and cure fraction. [P2]
- Data leakage and overfitting
  - Mitigation: Strict data splits by patient/site, nested CV, leakage checks; blinded external validation; preregistration. [2][3]
- Limited WSI availability in ICI cohorts
  - Mitigation: Proxy WSI biomarker tasks (MSI/TMB-high) to validate pipelines; collect local slides with IRB for pilot feasibility. [P8]
- Unclear clinical utility
  - Mitigation: Decision curves vs standard-of-care biomarkers; threshold analyses; clinician-in-the-loop review; early-stage evaluation per DECIDE-AI. [1][6]
- Regulatory/ethical and operational barriers
  - Mitigation: SPIRIT-AI protocol elements, CONSORT-AI reporting template for future trials; legal/data governance review. [5][4]

6) Stretch ideas or follow-up directions
- Spatial and single-cell-informed features: integrate deconvolution or single-cell-derived signatures of T-cell states to refine mechanism-aware predictors; align with Sade-Feldman T-cell states. [7]
- Multimodal pretraining: contrastive learning across WSI–omics; domain-agnostic embeddings to improve generalization. [P8]
- Trial design impact: simulate enrichment designs and adaptive randomization; consider time-to-event optimal phase II designs tailored to immunotherapy dynamics (e.g., designs accommodating delayed effects and non-proportional hazards). [P2]
- Federated multi-institution collaboration for privacy-preserving external validation at scale (prospective). 
- Health economics: link net benefit to cost-effectiveness under varying drug prices and toxicity disutility.

Optional next step
- Approve a 2-week sprint to acquire/validate IMvigor210 and melanoma cohorts, finalize the preregistered TRIPOD+AI analysis plan, and stand up the baseline pipelines (RNA/TMB/PD-L1) plus DCA scaffolding.

Citations
- [1] Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models — https://pubmed.ncbi.nlm.nih.gov/17099194/
- [2] TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning — https://pubmed.ncbi.nlm.nih.gov/38626948/
- [3] PROBAST+AI: updated risk of bias and applicability tool for prediction models — https://www.bmj.com/content/388/bmj-2024-082505
- [4] CONSORT-AI extension for clinical trials of AI interventions — https://www.nature.com/articles/s41591-020-1034-x
- [5] SPIRIT-AI guidance for AI intervention trial protocols — https://www.turing.ac.uk/research/research-projects/spirit-ai-and-consort-ai-initiative
- [6] DECIDE-AI: reporting guideline for early-stage clinical evaluation of AI decision support — https://pmc.ncbi.nlm.nih.gov/articles/PMC9116198/
- [7] Sade-Feldman M. et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy — https://www.sciencedirect.com/science/article/pii/S0092867418313941
- [8] Gide TN. et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 and Combination Therapy — https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30037-6
- [9] IMvigor210 resources (e.g., easierData consolidated access) — https://www.bioconductor.org/packages/release/data/experiment/html/easierData.html
- [10] Hugo W. et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy — https://pmc.ncbi.nlm.nih.gov/articles/PMC4808437/
- [P2] Piantanida S. et al. Mixture survival models methodology: an application to cancer immunotherapy assessment — http://arxiv.org/abs/1911.09765v1
- [P8] Bychkov D. et al. Fully transformer-based biomarker prediction from colorectal cancer histology — http://arxiv.org/abs/2301.09617v2